Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avotermin

Drug Profile

Avotermin

Alternative Names: Human recombinant TGF beta 3; Juvista; RN 1001

Latest Information Update: 15 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Renovo
  • Developer Renovo; Takeda
  • Class Recombinant proteins; Transforming growth factors
  • Mechanism of Action Transforming growth factor beta3 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Scars; Vascular restenosis

Most Recent Events

  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 03 Mar 2011 Shire terminates its licence for avotermin in USA, Canada and Mexico
  • 03 Mar 2011 Discontinued - Phase-III for Scars in Denmark (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top